



Atty. Dkt. No. DOCKET NO. 53466/295

GAU1644
BOX SEQ
B/24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yasuo Koishihara

Title: INHIBITOR OF LYMPHOCYTE ACTIVATION

Appl. No.: 09/760,723

RECEIVED

MAY 31 2001

Filing Date: 01/17/2001

TECH CENTER 1600/2900

Examiner: Unassigned

Art Unit: 1644

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Application Containing Sequence Disclosures mailed March 28, 2001, please delete the previously filed sequence listing (pages 42-44) and substitute with the attached sequence listing (pages 1-8).

REMARKS

Applicant submits this Amendment to delete the previously filed Sequence Listing and substitute the Sequence Listing filed concurrently herewith. Applicant respectfully requests examination on the merits of this application.

Respectfully submitted,

Michael D. Kammerer

By Reg. No. 32,904, Jr.

Date May 29, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5571
Facsimile: (202) 672-5399

Harold C. Wegner
Attorney for Applicant
Registration No. 25,258



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/760,723	01/17/2001	Yasuo Koishihara	053466/0295

CONFIRMATION NO. 4861

FORMALITIES LETTER



OC000000005913688

Harold C. Wegner
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W. Suite 500
Washington, DC 20007-5109

Date Mailed: 03/28/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

S. Joseph

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED

MAY 31 2001

TECH CENTER 1600/2900